Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Ascendis Pharma A (ASND) over the last 9 years, with Q3 2025 value amounting to $4.6 million.

  • Ascendis Pharma A's Depreciation & Amortization (CF) fell 262.28% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 million, marking a year-over-year decrease of 312.9%. This contributed to the annual value of $18.7 million for FY2024, which is 585.22% down from last year.
  • As of Q3 2025, Ascendis Pharma A's Depreciation & Amortization (CF) stood at $4.6 million, which was down 262.28% from $4.7 million recorded in Q2 2025.
  • Ascendis Pharma A's 5-year Depreciation & Amortization (CF) high stood at $5.2 million for Q4 2023, and its period low was $4.2 million during Q2 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $4.7 million (2025), whereas its average is $4.7 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first surged by 9753.5% in 2021, then plummeted by 1037.36% in 2024.
  • Over the past 5 years, Ascendis Pharma A's Depreciation & Amortization (CF) (Quarter) stood at $4.8 million in 2021, then fell by 3.02% to $4.6 million in 2022, then rose by 12.47% to $5.2 million in 2023, then decreased by 10.37% to $4.7 million in 2024, then fell by 2.15% to $4.6 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $4.6 million for Q3 2025, versus $4.7 million for Q2 2025 and $4.7 million for Q1 2025.